Hepatitis C Research

News & Articles

 2003

DEC 2003

Back to 2004 News

  Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy.
  Anadys Pharmaceuticals Reports Interim Results of Phase 1B Clinical Trial of Isatoribine -ANA245- in Patients Infected with Hepatitis C Virus
  N.Y. Panel OKs New Liver Transplant Rules
  Company in Hepatitis Case Violated Rules
  Drug Maker Recalls Acetaminophen Tablets
  Vitamin E and vitamin C treatment improves fibrosis in patients with
nonalcoholic steatohepatitis.

 

Nov 2003

    Chronic Hepatitis C More Severe, Less Treated in Elderly
    Non-Invasive Technique Measures Liver Elasticity in Chronic Viral Hepatitis
    Characteristics of Upper Abdominal Pain in Those with Chronic Liver Disease
    Blood ammonia determination in cirrhosis: Still confusing after all these years?
    Maxim Announces Publication of Research Results Supporting Use of Histamine in Treatment of Hepatitis C
 
    Click On This Link To Read A Great Article On HCV : You Will Be Taken Away From Our Site

http://www.kansascity.com/mld/kansascity/news/special_packages/hepatitis/

Study Estimates in Year 2030, Deaths from HIV in the US Will Decline to 4,200 - 6,700, While HCV-related Deaths Will Peak at 14,000 - 19,000
    Flu Vaccination in Transplant Recipients?

Oct 2003

     

Duke University to Lead First Comparative Trial of Hepatitis C Therapies

Therapies pegylated interferon alfa-2b PEG-INTRON and PEGASYS
    The effect of early treatment in children with chronic hepatitis
    SCICLONE COMPLETES ENROLLMENT OF 500 PATIENTS IN
FIRST OF TWO PHASE 3 HEPATITIS C TRIALS
    The Efficacy of Daily Interferon Alfa Plus Ribavirin in Treatment-naive Patients with Chronic Hepatitis C
    Interferon Alfa Combined with Ribavirin with and without Amantadine in Nonresponders with Chronic Hepatitis C
    Isis Optimistic About Latest Antisense Compounds
by Deena Beasley
    Impact of High-Dose Interferon Induction and Ribavirin Therapy in Patients With Chronic Hepatitis C Relapsing After or Not Responding to Interferon Monotherapy
    Treatment of Hepatitis B and C Virus Infections in Immune Compromised Individuals
    Taming Hepatitis C: High stakes but low odds
    Research Findings Suggest Potent Antiviral Activity and Favorable In Vitro Resistance Profile for Vertex's Investigational HCV Protease Inhibitor VX-950
    Experimental Hepatitis C Drug 'Promising'
    New Study Demonstrates Benefits of Hepatitis C Therapy Among
Previously Under-Treated Patient Population
    Idun Pharmaceuticals Reports Positive Data for First Oral Clinical Trial in HCV Patients

     Sep 2003

High body mass index is a risk factor for nonresponse to treatment in
hepatitis C
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.
A Summary Review of Steps in the Management of Chronic Hepatitis C

          Aug 2003   

    Relapsers Can Be Successfully Re-treated with Interferon Alfa Induction Combined with Ribavirin/Amantadine
    Should PEG-Intron Be Given Twice Weekly to Improve HCV Clearance in Genotype 1 Patients?
    FDA Grants Marketing Approval to Schering-Plough's Rebetol for Treatment of Hepatitis C in Children
    Favorable prognosis of hepatitis C after interferon therapy
 
    Pegasys Therapy Shortened for Some European Hepatitis C Patients Hepatitis C Research
    Following Treatment with Interferon and Ribavirin, Fibrosis Regression Is Greater in HCV Genotype 1 Sustained Responders But Also May Decrease in Non Responders
    Sustained Viral Response to Treatment Is Associated with a Reduction of Steatosis in Genotype 3 HCV Patients
    Dynamics of alanine aminotransferase during hepatitis C virus treatment.
    A Simple Index Can Predict Both Significant Fibrosis and Cirrhosis in HCV Patients
    Enzyme Therapy Attacks Liver Tumors in Second Phase Study

July 2003

    Twice-a-day versus once-a-day interferon-beta therapy in chronic hepatitis C.
    International Study Will Evaluate Efficacy of Pegasys and Copegus in HCV Patients Who Are Non Responders to PEG-Intron and Rebetol
    Early Responders to PEG-Intron (peginterferon alfa-2b) Plus Ribavirin Have a Significant Reduction in HCV RNA at 48 hours That May Be Pivotal in Achieving a Sustained Viral Response
    Effect of Ribavirin on Hepatitis C Viral Kinetics in Patients Treated with Pegylated Interferon
    Roche's Pegasys Effective To Treat Hepatitis C -Studies
    New Pegasys Trial to Enroll Hepatitis C Patients Not Helped by PEG-Intron
    Spontaneous and treatment-induced viral clearance in acute hepatitis C
    Cost-effectiveness of treatment for chronic hepatitis C infection
    Combination Therapy with Interferon Alfa Plus Ribavirin Seems to Be an Important Advance in the Treatment of Children and Adolescents with Chronic HCV
    High Rate of Spontaneous and Treatment-Induced Clearance of Acute Hepatitis C Infection
    Alcohol Ups Hepatitis C Virus Replication
    Drugs Now In Pipeline May Shorten, Ease Hepatitis C Treatment

May 2003

    Triple therapy regimens containing amantadine offer hope for HCVnonresponders
    Extending Peginterferon Plus Ribavirin Therapy to 72 Weeks in Late Responders with Genotype 1 Chronic HCV Can Produce a Sustained Virologic Response
Alcohol Diminishes Therapeutic Effect of Interferon Alfa and May Be Cofactor in HCV Disease Progression
    Study: 99 Percent of Pegasys Responders Virus Free Up to Four Years Later
Twice weekly PegInterferon in Genotype 1

March 2003

 

 

Hepatocytes Experimentally Converted to Pancreatic Cells by Gene Transfer
    Hepatitis C Infection Causes Cognitive Impairment in a Cohort of Patients with Mild Liver Disease
    Interdisciplinary Care Works For Hepatitis Patients At Psychiatric Risk
    PEG-Intron + Ribavirin Produces a Biphasic Decline in HCV Levels and Higher Doses Accelerate Viral Clearance
    Induction Dose of PEG-Intron Is More Effective Than Fixed Dose in Combination with Ribavirin for Chronic HCV Patients Nonresponsive to a Previous Treatment
    Retreatment with PEG-Intron Plus Ribavirin Shows Limited Benefit in Patients with Chronic Hepatitis C Not Responding to Previous Treatment with Standard Interferon and Ribavirin
    Interim Results of Observational Study of Patients Treated for Chronic Hepatitis C in France
    Early Virologic Response (EVR) at Week 8 Is More Predictive of Sustained Response to Pegylated Interferon/Ribavirin Therapy Than at Week 12
    Liver Fibrosis Regresses Better with PEG-Intron and Ursodeoxycholic Acid Treatment Than with Spontaneous Recovery
    Pharmacokinetics of Pegasys Compared to PEG-Intron in Treatment-Naïve Patients with Chronic Hepatitis C
    Projecting future complications of chronic hepatitis C in the United States
    How Often Should Biopsy Be Performed?
    HCV & HCV/HIV Rates of Fibrosis Progression

Feb 2003

Hepatology Highlights Feb 2003
Treating Hard To Treat Patients
Top Abstracts in Hepatitis C Research
H.I.V. Lessons Used in Hepatitis C Treatment (Information on HCV Treatments)
    Adherence to HCV Therapy the (80/80/80) Rule
    Anadys Reports Completion of Phase IA Study of ANA245
Generic Ribavirin on the Way
Rate of natural disease progression in patients with chronic hepatitis C

Jan 2003

Removing HCV From Blood in Two Hours
Viral Kinetics in Treatment-Naïve Patients with Pegasys Versus PEG-Intron

 

 

The Liver Meeting Boston 2003 54th Annual Meeting of the American Association for the Study of Liver Diseases

NEW

Read all the Latest Reports Just In

Click Below

 The American Association for the Study of Liver Diseases,

October 24 - 28, 2003 Boston, MA

 

(Back to : Reports from Digestive Disease Week 2003:

Orlando Fl, May 17-22

(Back to : 38th Annual Meeting of the European Association for the Study of the Liver 
Istanbul, Turkey. March 28-April 1, 2003 )

 

Back to : AASLD ( American Association for the Study of Liver Diseases 2001)

 

 
HOME Liver Cancer
FAQ Great Place To Start Autoimmune Hepatitis
Have You Just Been Diagnosed ? Other Medical Conditions & HCV
Glossary HCV Worldwide News & Research
History Of HCV HCV News Archives 2001-2002
Your Liver Functions Internet Conference Reports on All New and Current HCV Therapies
Symptoms Of HCV Nutrition & HCV
Transmission Of HCV Interviews: Members & Professionals
Sex And HCV HCV Support Groups Listed By State
Understanding Your Blood Tests  Labs Transplant Support Groups Listed By State
Monitoring Blood Work On Treatment Insurance, Financial Aid & Free Meds
Liver Biopsy Understanding Your Results How to Find a Doctor & What to Ask
Viral Loads Members Share Their First Shot Experience
Genotypes Shared Stories From Our  Members
Infergen Your Questions & HCV
 Inhibitors &  New Therapies Chat Room & Message Boards
Peg Intron & Pegasys Books On HCV
Help With Side Effects During Treatment Food For The Soul Inspirational Stories
Drug Interactions & Treatment Informative Links
Latest HCV Trials Pictures Of Our Members
Liver Fibrosis What's New at Janis and Friends
Cirrhosis Sign Our Guestbook
Transplants Contact Us mailto:JansDream@angelhaven.com
Current Transplant Research In Memory Of Janis

Reviewed March 2004